best bpc 157 dose BPC-157 Dosage Calculator: Units, mL & Mixing Guide bpc-157 tb-500 protocol bpc 157

Quick reference table Further reading Peptide stability & lyophilisation review searches Peptide solubility & formulation review searches Internal links BPC-157 research material TB-500 research material GHK-Cu research material How to read an HPLC chromatogram Peptide storage & handling lab SOP Knowledge Hub Updated: 14 Nov 2025 Tide Labs supplies materials strictly for laboratory research use only

The 2-hour SDS treatment was continued every other day, with 2 M svL4 in PBS alone or mixed with 1 M Dex sodium phosphate (catalog number 2480645, Henry Schein, Melville, NY) in 0.2 ml of PBS applied daily for another 5 days

A large preclinical toxicity program run across mice, rats, rabbits, and dogs found BPC-157 well tolerated with no serious treatment-related toxicity, no identifiable lethal dose, and no genotoxic or teratogenic signal, which is the strongest safety data point available by Xu 2020

Details SHOW SMILES / InChI SMILES CC(O)=O.CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(O)=O)NC(=O)CN)C(=O)N[C@@H](C(C)C)C(O)=O InChI InChIKey=LIKSGLHWFDSWDW-OIBXLTBVSA-N InChI=1S/C62H98N16O22.C2H4O2/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64;1-2(3)4/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100);1H3,(H,3,4)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-;/m0./s1 Body protective compound 15 also known as bepecin, BPC 157 or PL 14736, a small, chemically synthesized pentadecapeptide which has been shown to be safe in clinical trials for inflammatory bowel disease and may be able to cure intestinal anastomosis dehiscence

J., Balaish, M., Wadaguchi, M., Kong, L

This is driven by the likelihood of subchondral bone changes as a consequence of failed repair, particularly if the first attempt involved disruption of the tidemark for marrow recruitment